10. BREAST AND OVARIAN ONCOLOGY PROGRAM Andrew Berchuck, M.D., H. Kim Lyerly, M.D. and Victoria Seewaldt, M.D., Co-Leaders Major diagnostic and therapeutic modalities for the management of breast and ovarian cancer have contributed to the improved care of the cancer patient and the patient at-risk for cancer. Nonetheless, in order to develop the next generation of target-defined therapies for breast and ovarian cancer will need a multidiseiplinary approach to 1) define early events in breast and ovarian carcinogenesis and 2) translate these advances into novel therapeutic approaches. The Breast and Ovarian Cancer Program includes 52 member investigators from 17 departments within Duke University. Total funding includes $11.3M of federally funded grant support. The goal of this program is to foster scientific interactions between members of the Duke Comprehensive Cancer Center who have basic, clinical, translational, and population research interests in breast and ovarian cancer. In order to provide and maintain a dynamic forum for scientific discourse and collaboration, the Program focuses on specific aspects of breast and ovarian cancer within scientific interest groups. Within the domain of the Breast and Ovarian Cancer Program we developed seven subprograms that draw from our scientific strengths in breast and ovarian cancer research: 1) Hormone receptor pharmacology;2) Cancer genetics and molecular epidemiology; 3) Cancer genomics;4) Tumor immunology and vaccine development;5) Experimental therapeutics; 6) Molecular carcinogenesis and cancer prevention;7) Breast cancer detection and imaging. The diversity of interest and experimental approaches used by the members of the BOCP represents an effective asset for fostering cross-fertilization of ideas aimed at understanding breast and ovarian cancer. Since the last competing renewal, members of the BOCP have published 893 papers in primary peer-reviewed ournals of which 498 or 57% bear directly on breast and/or ovarian cancer and 35 o% are the result of either ntra- or inter-programmatic collaboration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-35
Application #
7764695
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-01-01
Budget End
2009-12-31
Support Year
35
Fiscal Year
2009
Total Cost
$37,597
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766
Abdi, Khadar; Lai, Chun-Hsiang; Paez-Gonzalez, Patricia et al. (2018) Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat Commun 9:1655
Hudson, Kathryn E; Rizzieri, David; Thomas, Samantha M et al. (2018) Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol :
Fayanju, Oluwadamilola M; Park, Ko Un; Lucci, Anthony (2018) Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. Ann Surg Oncol 25:512-519
Porter, Laura S; Fish, Laura; Steinhauser, Karen (2018) Themes Addressed by Couples With Advanced Cancer During a Communication Skills Training Intervention. J Pain Symptom Manage 56:252-258

Showing the most recent 10 out of 513 publications